October 4, 2013

AmerisourceBergen on Friday announced the company will hold its annual manufacturer summit, ThinkLive 2013, Oct. 7 to 8 at the Fairmont Hotel in Dallas.

September 20, 2013

Specialty infusion pharmacy company Biomed Pharmaceuticals has named Craig Mears as SVP sales and marketing, the company said Friday.

September 16, 2013

Actavis has launched a generic drug for post-shingles pain under an agreement with the branded drug's manufacturers, the company said Monday.

August 8, 2013

The Supreme Court usually has a lot on its plate in any given year, but this year's term included a pretty big case for the pharmaceutical industry: the Federal Trade Commission v. Actavis, which concerned legal settlements between branded and generic drug makers that often occur when the latter attempts to market a generic drug before the former's patents have expired.

August 8, 2013

The urgency behind Diplomat's launch of its Retail Specialty Network isn't hard to fathom. As the growth momentum in pharmaceuticals shifts from traditionally developed drugs to more complex and expensive specialty and biotech products, traditional pharmacies without access to these specialized medicines — and the patients who depend on them — find themselves stranded in a receding market like boats at low tide.

August 7, 2013

Teva Women’s Health, the U.S subsidiary of Teva Pharmaceuticals, announced on Wednesday that the emergency contraceptive Plan B One-Step (levonorgestrel) tablet 1.5 mg is now widely available at retail with no age or point-of-sale restrictions.

August 5, 2013

Amneal Pharmaceuticals has introduced five new generic drugs, the company said.

July 31, 2013

The Food and Drug Administration has given Lupin Pharmaceuticals tentative approval to two of its products, the company said Wednesday.

July 24, 2013

The Food and Drug Administration has granted the manufacturer of Plan B One-Step exclusive marketing rights for three years, according to published reports.

July 2, 2013

UrgentRx on Monday named Michael Valentino to the company's board.

June 25, 2013

The Food and Drug Administration has given special designation to a drug made by Raptor Pharmaceuticals for a rare metabolic disease.

June 20, 2013

Tris Pharma has hired a former buyer from AmerisourceBergen to head its generic drug business, the company said.

June 13, 2013

Drug maker Actavis is working with nonprofit pharmaceutical company Medicines360 to make low-cost intrauterine devices available to women, the two said.

June 11, 2013

Aceto Corp. will sell an authorized generic version of a drug used to treat a rare but devastating degenerative disorder.

June 10, 2013

Drug maker Amag Pharmaceuticals has licensed the U.S. commercial rights to a treatment for a common side effect of cancer treatments from another company, Amag said Monday.

June 4, 2013

The Center for Healthcare Supply Chain Research, HDMA’s nonprofit research foundation, and Genentech on Tuesday honored Robert Belknap, executive director of trade sales and operations for Boehringer Ingelheim Pharmaceuticals, with the 2013 Nexus Award for Lifetime Achievement.

June 4, 2013

At the 2013 Business and Leadership Conference in Orlando, Fla., HDMA honored pharmaceutical and consumer product manufacturers during the presentation of the 2013 Distribution Industry Awards for Notable Achievements in Healthcare.

June 4, 2013

A subsidiary of Aceto Corp. has launched a generic treatment for seasonal and perennial allergies, the company said Tuesday.

May 31, 2013

India-based Sun Pharmaceutical Industries may buy Sweden-based Meda for $5 billion to $6 billion, according to published reports.

May 29, 2013

Avion Pharmaceuticals, a specialty pharmaceutical company, recently announced the launch of Prenate Chewable, a chewable, chocolate-flavored version of the original Prenate prescription prenatal vitamin.

May 28, 2013

Anglo-Swedish drug maker AstraZeneca will buy Omthera Pharmaceuticals for $323 million, the two companies said.

May 21, 2013

A federal appellate court has ruled in favor of Mylan in a case involving a drug for chronic obstructive pulmonary disease, the drug maker said.

May 7, 2013

Federal prescription drug programs are more susceptible to waste, fraud and abuse because of the lack of transparency and oversight of mail-order pharmacy, proclaimed the Taxpayers Protection Alliance on Tuesday in a report called “The Expensive Truth Behind Taxpayer-Funded Mail Order Pharmaceuticals.”

May 7, 2013

The global market for biosimilars will be worth nearly $2.5 billion this year, according to a new study.